Insulet Corporation (NASDAQ:PODD) Shares Bought by Jennison Associates LLC

Jennison Associates LLC boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 52.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 241,717 shares of the medical instruments supplier's stock after acquiring an additional 83,375 shares during the period. Jennison Associates LLC owned 0.34% of Insulet worth $63,477,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PODD. Larson Financial Group LLC grew its stake in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet in the fourth quarter worth approximately $42,000. Golden State Wealth Management LLC boosted its holdings in shares of Insulet by 553.1% in the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 177 shares during the last quarter. Coppell Advisory Solutions LLC boosted its holdings in shares of Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 162 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Insulet by 23.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after buying an additional 59 shares during the last quarter.

Insider Transactions at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president directly owned 23,180 shares of the company's stock, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.39% of the stock is owned by company insiders.

Insulet Stock Up 0.3%

Insulet stock traded up $0.78 during midday trading on Friday, hitting $284.23. 349,138 shares of the company's stock were exchanged, compared to its average volume of 717,682. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The firm has a 50-day moving average of $309.07 and a two-hundred day moving average of $280.99. The company has a market cap of $20.00 billion, a PE ratio of 51.12, a P/E/G ratio of 2.54 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same period in the previous year, the firm earned $0.73 EPS. The business's quarterly revenue was up 28.8% on a year-over-year basis. As a group, analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PODD. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a report on Tuesday, May 13th. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a report on Monday, April 28th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Barclays lifted their price target on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. Finally, Wall Street Zen downgraded shares of Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.